NAAA
VRTX icon

New Age Alpha Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

New Age Alpha Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.1M Sell
11,418
-1,204
-10% -$561K 0.24% 119
2025
Q4 		$5.72M Sell
12,622
-1,317
-9% -$568K 0.25% 104
2025
Q3 		$5.46M Sell
13,939
-1,761
-11% -$736K 0.23% 121
2025
Q2 		$6.99M Buy
15,700
+2,563
+20% +$1.18M 0.31% 74
2025
Q1 		$6.37M Sell
13,137
-170
-1% -$79.2K 0.29% 90
2024
Q4 		$5.36M Buy
+13,307
New +$6.17M 0.22% 131

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

New Age Alpha Advisors's VRTX Position: Q1 2026 in Review

New Age Alpha Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 9.5% in Q1 2026, selling an estimated $561K and leaving 11,418 shares worth $5.1M. The position accounts for 0.24% of the portfolio, ranked #119.

New Age Alpha Advisors first reported a position in VRTX in Q4 2024 and has held it in 6 quarters since. The position peaked at $6.99M in Q2 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • New Age Alpha Advisors held 11,418 shares of Vertex Pharmaceuticals worth $5.1M as of Q1 2026.
  • New Age Alpha Advisors sold 1,204 Vertex Pharmaceuticals shares in Q1 2026, an estimated $561K.
  • Vertex Pharmaceuticals made up 0.24% of New Age Alpha Advisors's portfolio in Q1 2026, its #119 holding.
  • New Age Alpha Advisors first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • New Age Alpha Advisors's Vertex Pharmaceuticals position peaked at $6.99M in Q2 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on New Age Alpha Advisors's 13F filing for Q1 2026, filed 11 May 2026.